Brought to you by 
Fate Therapeutics closes $36mm Series B round
29 Aug 2013
Executive Summary
Fate Therapeutics (stem cell modulators) raised $30mm through its Series B round. OVP Venture Partners led and was joined by returning buyers Arch Venture Partners, Polaris Venture Partners, and Venrock. For the first time since its founding in 2007, Fate also saw participation in the financing from corporate-backed funds including Astellas Venture Management, Genzyme Ventures, and a third undisclosed corporate investor. OVP takes a seat on Fate's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fate Therapeutics closes $36mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice